Published in Eur J Cancer on March 23, 2010
Low-frequency variants in HMGA1 are not associated with type 2 diabetes risk. Diabetes (2011) 1.05
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
The HMGA1-IGF-I/IGFBP system: a novel pathway for modulating glucose uptake. Mol Endocrinol (2012) 0.90
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Front Endocrinol (Lausanne) (2015) 0.85
Differential transcriptomic analysis of spontaneous lung tumors in B6C3F1 mice: comparison to human non-small cell lung cancer. Toxicol Pathol (2012) 0.84
Sp1 facilitates DNA double-strand break repair through a nontranscriptional mechanism. Mol Cell Biol (2012) 0.83
Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells. Front Endocrinol (Lausanne) (2015) 0.81
Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways. Front Oncol (2016) 0.75
TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1. Oncotarget (2016) 0.75
IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1. Elife (2017) 0.75
Diabetes and cancer. Endocr Relat Cancer (2009) 5.04
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 3.53
Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol (2006) 3.44
Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev (2009) 3.37
Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol (2013) 2.80
Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab (2004) 2.71
The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem (2008) 2.20
Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett (2004) 2.17
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem (2002) 2.15
Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab (2013) 1.86
Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst (2009) 1.80
Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab (2010) 1.79
Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology (2012) 1.69
Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat Med (2005) 1.64
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res (2005) 1.58
The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev (2008) 1.52
A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab (2002) 1.44
Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism (2002) 1.40
Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev (2013) 1.39
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res (2009) 1.37
Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol (2003) 1.32
Subclinical hypothyroidism in early childhood: a frequent outcome of transient neonatal hyperthyrotropinemia. J Clin Endocrinol Metab (2002) 1.32
Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 1.31
Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab (2004) 1.30
HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget (2013) 1.29
Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology (2006) 1.23
Risk factors for congenital hypothyroidism: results of a population case-control study (1997-2003). Eur J Endocrinol (2005) 1.22
Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One (2011) 1.22
Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett (2007) 1.22
The AT-hook of the chromatin architectural transcription factor high mobility group A1a is arginine-methylated by protein arginine methyltransferase 6. J Biol Chem (2005) 1.21
Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol (2006) 1.18
Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets (2013) 1.18
Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene (2005) 1.16
HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res (2006) 1.16
Thyroid hemiagenesis: prevalence in normal children and effect on thyroid function. J Clin Endocrinol Metab (2003) 1.14
Longitudinal study of thyroid function in children with mild hyperthyrotropinemia at neonatal screening for congenital hypothyroidism. J Clin Endocrinol Metab (2008) 1.14
A polypyrimidine/polypurine tract within the Hmga2 minimal promoter: a common feature of many growth-related genes. Biochemistry (2002) 1.14
HMGA molecular network: From transcriptional regulation to chromatin remodeling. Biochim Biophys Acta (2009) 1.13
In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene (2002) 1.12
Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets (2009) 1.11
The second AT-hook of the architectural transcription factor HMGA2 is determinant for nuclear localization and function. Nucleic Acids Res (2007) 1.10
The role of metformin in the management of NAFLD. Exp Diabetes Res (2011) 1.09
Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A. J Biol Chem (2012) 1.09
Molecular dissection of the architectural transcription factor HMGA2. Biochemistry (2003) 1.09
Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One (2013) 1.09
Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res (2009) 1.08
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis (2003) 1.07
A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Int J Biochem Cell Biol (2008) 1.05
A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet (2002) 1.05
Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab (2008) 1.05
Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol (2006) 1.05
Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors. J Clin Endocrinol Metab (2002) 1.04
During apoptosis of tumor cells HMGA1a protein undergoes methylation: identification of the modification site by mass spectrometry. Biochemistry (2003) 1.04
Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A. J Biol Chem (2003) 1.04
Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem (2011) 1.03
Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology (2004) 1.03
Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology (2003) 1.01
Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer (2007) 1.01
An ATG repeat in the 3'-untranslated region of the human resistin gene is associated with a decreased risk of insulin resistance. J Clin Endocrinol Metab (2002) 1.00
BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett (2003) 1.00
Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab (2011) 0.99
Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis (2003) 0.99
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
HEX expression and localization in normal mammary gland and breast carcinoma. BMC Cancer (2006) 0.98
The intricate involvement of the Insulin-like growth factor receptor signaling in mild traumatic brain injury in mice. Neurobiol Dis (2010) 0.98
Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. J Clin Endocrinol Metab (2009) 0.98
New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cell Signal (2012) 0.98
High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) (2005) 0.97
Insulin has multiple antiamyloidogenic effects on human neuronal cells. Endocrinology (2012) 0.96
Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology (2009) 0.96
Autocrine activation of the local insulin-like growth factor I system is up-regulated by estrogen receptor (ER)-independent estrogen actions and accounts for decreased ER expression in type 2 diabetic mesangial cells. Endocrinology (2004) 0.95
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci (2013) 0.94
IGF signaling defects as causes of growth failure and IUGR. Trends Endocrinol Metab (2008) 0.94
Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology (2004) 0.93
The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. Int J Exp Pathol (2008) 0.93